STOCK TITAN

Nyxoah SA Ordinary Shares - NYXH STOCK NEWS

Welcome to our dedicated page for Nyxoah SA Ordinary Shares news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA Ordinary Shares stock.

Nyxoah SA Ordinary Shares (symbol: NYXH) is at the forefront of medical technology, focusing on innovative solutions to address Obstructive Sleep Apnea (OSA). The company is committed to enhancing the lives of individuals suffering from sleep-disordered breathing conditions through its state-of-the-art products and services.

Nyxoah's flagship product, the Genio system, is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe OSA. This user-centered system provides an effective and non-invasive treatment option for a condition that has been linked to increased mortality risks and various comorbidities, including cardiovascular diseases, depression, and stroke.

The Genio system stands out in the market due to its unique approach, focusing on bilateral stimulation to open the airway during sleep, thereby improving the quality of life for patients. The development and commercialization of this innovative platform underscore Nyxoah's commitment to addressing critical health issues with cutting-edge technology.

Recent achievements of Nyxoah include advancements in clinical trials, expansion into new markets, and strategic partnerships that underscore the company's growth potential and dedication to innovation. Financially, Nyxoah has shown resilience and strategic foresight, ensuring robust investment in research and development to maintain its competitive edge.

Nyxoah continually updates its stakeholders with the latest company news, ensuring transparency and fostering investor confidence. With its headquarters in Belgium, Nyxoah is well-positioned to expand its global presence and continue its mission of providing effective solutions for OSA and related conditions.

Stay informed with the latest updates and developments from Nyxoah to keep track of their performance, events, and strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
-
Rhea-AI Summary

Nyxoah SA announced significant shareholding updates on April 20, 2023. The company received two transparency notifications regarding large shareholdings. Together Partnership has surpassed the 10% threshold, holding 2,948,285 shares or 10.42% of voting rights as of March 30, 2023. Simultaneously, ResMed Inc. crossed the 5% threshold, holding 1,499,756 shares or 5.30% of voting rights on the same date. The total number of voting rights on that date was 28,286,985. These notifications comply with the regulations set forth in the Act of May 2, 2007.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.06%
Tags
none
-
Rhea-AI Summary

Mont-Saint-Guibert, Belgium, April 17, 2023 – Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) announced updates regarding its share capital following the issuance of new shares. The company's total share capital is now EUR 4,923,807.45, with 28,661,985 voting rights available from ordinary shares. Additionally, the report outlines various warrant issuances that allow the holders to subscribe to a total of 2,501,875 securities carrying voting rights. This information is disclosed in accordance with the legal requirement to report large shareholdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
Rhea-AI Summary

Nyxoah Raises $3 Million from Equity Offering

On April 13, 2023, Nyxoah announced the successful raising of $3 million through its At-the-Market (ATM) equity offering program, initiated on December 22, 2022. The funds will be utilized for general corporate purposes. This offering was executed under a shelf registration statement effective since January 6, 2023, allowing the company to capitalize on favorable market conditions.

Nyxoah specializes in innovative solutions for treating Obstructive Sleep Apnea (OSA), with its key product, the Genio® system, already CE marked in Europe and under FDA study for U.S. approval. The company aims to enhance patient quality of life by addressing OSA effectively.

Despite the positive fundraising news, Nyxoah continues to face market uncertainties inherent in medical technology development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.38%
Tags
none
-
Rhea-AI Summary

Mont-Saint-Guibert, Belgium, March 31, 2023 – Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) announced updated information on its voting rights and share capital. The total share capital now stands at EUR 4,859,382.45, with 28,286,985 ordinary shares carrying voting rights. Following recent share issues, there are also multiple warrants entitling holders to subscribe to additional securities, including 55 from the 2016 ESOP Warrants, 100 from the 2018 ESOP Warrants, 430,500 from the 2020 ESOP Warrants, 1,326,375 from the 2021 ESOP Warrants, and 700,000 from the 2022 ESOP Warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary

Nyxoah has successfully raised $2.8 million through an at-the-market equity offering as part of a broader $50 million program initiated in December 2022. The funding comes from a historical shareholder, Cochlear Limited, and will be allocated for general corporate purposes. This offering is conducted under a shelf registration statement filed with the SEC. The company is known for its Genio® system, a CE marked technology for treating Obstructive Sleep Apnea (OSA), and is currently seeking FDA approval in the U.S. with its ongoing DREAM IDE pivotal study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.68%
Tags
none
Rhea-AI Summary

Nyxoah announced a $15 million private placement financing on March 23, 2023, issuing 2,047,544 shares at €6.52 each (approx. $7.10). Gross proceeds of €13.35 million will support corporate purposes, with closing expected around March 30, 2023. Key shareholders, including ResMed and Robert Taub, participated in the offering. Nyxoah specializes in treatments for Obstructive Sleep Apnea (OSA), with its lead product, the Genio® system, having received CE Mark approval. The company is also conducting the DREAM IDE study for FDA approval in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none

FAQ

What is the current stock price of Nyxoah SA Ordinary Shares (NYXH)?

The current stock price of Nyxoah SA Ordinary Shares (NYXH) is $8.01 as of December 20, 2024.

What is the market cap of Nyxoah SA Ordinary Shares (NYXH)?

The market cap of Nyxoah SA Ordinary Shares (NYXH) is approximately 298.7M.

What is Nyxoah SA's core business?

Nyxoah SA focuses on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA).

What is the Genio system?

The Genio system is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe Obstructive Sleep Apnea (OSA).

What conditions does Nyxoah's Genio system address?

The Genio system targets Obstructive Sleep Apnea (OSA), which is associated with increased mortality risk and comorbidities like cardiovascular diseases, depression, and stroke.

How does Nyxoah update its stakeholders?

Nyxoah ensures transparency by continually updating stakeholders with the latest company news, performance information, and strategic initiatives.

Where is Nyxoah SA headquartered?

Nyxoah SA is headquartered in Belgium, with its innovative solutions reaching markets worldwide.

What makes the Genio system unique?

The Genio system is unique due to its bilateral stimulation approach, providing an effective and non-invasive treatment for OSA by opening the airway during sleep.

What recent achievements has Nyxoah accomplished?

Nyxoah has made significant strides in clinical trials, market expansion, and strategic partnerships, highlighting its growth potential and commitment to innovation.

What is OSA?

Obstructive Sleep Apnea (OSA) is a sleep disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to breathing interruptions.

Why invest in Nyxoah SA?

Nyxoah SA offers innovative solutions for OSA, a condition with significant health risks. The company's continuous advancements, strategic partnerships, and commitment to innovation make it a promising investment opportunity.

What are Nyxoah's future plans?

Nyxoah aims to expand its global presence, enhance its product offerings, and continue investing in research and development to bring effective solutions for sleep-disordered breathing conditions.

Nyxoah SA Ordinary Shares

Nasdaq:NYXH

NYXH Rankings

NYXH Stock Data

298.67M
22.46M
41.74%
35.37%
0.12%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Mont-Saint-Guibert